Results from a cardiovascular prevention campaign in persons aged 45-64 years

International Journal of Clinical Practice

Volumn 57, Issue 5, 2003, Pages 430-434

  Devroey, Dirk ^a   De Swaef, N ^a   Coigniez, P ^a   Vandevoorde, J ^a   Kartounian, J ^a   Betz, W ^a  

^a FREE UNIVERSITY OF BRUSSELS   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; BELGIUM; BLOOD PRESSURE MONITORING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MALE; MASS SCREENING; MEDICAL EXAMINATION; OBESITY; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

BELGIUM; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CHOLESTEROL; DIABETIC ANGIOPATHIES; FEMALE; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; MALE; MASS SCREENING; MIDDLE AGED; OBESITY; SMOKING; TRIGLYCERIDES;

EID: 0038081304     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Smith WC, Lee AJ, Crombie IK, Tunstall-Pedoe H. Control of blood pressure in Scotland: the rule of halves. BMJ 1990; 300: 981-983.
2. Black HR. Optimal blood pressure: how low should we go? Am J Hypertens 1999; 12: S113-S120.
3. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
4. Wingard DL, Barrett-Connor E. Heart disease and diabetes. In: Harris MI, Couric CC, Reiber G et al, Eds. Diabetes in America, 2nd edn. Washington DC: US Printing Office; NIH publication 1995-1468; 429.
5. Prevention of coronary heart disease in clinical practice. Recommendations of the second joint task force of European and other societies on coronary prevention. Eur Heart J 1998; 19: 1434-1503.
6. Florence JA, Yeager BF. Treatment of type 2 diabetes mellitus. Am Fam Phys 1999; 59: 2835-2844.
7. Gaster B, Hirsch IB. The effects of improved glycemic control in complications in type 2 diabetes. Arch Intern Med 1998; 158: 134-140.
8. van den Berg PJ, van Dalsen CL, de Rooij RA et al. Cardiovascular health check in the elderly in one general practice: does it offer new information and lead to interventions? Fam Pract 1999; 16: 389-394.
9. McMenamin JP. Screening for coronary heart disease risk among men in a general practice. NZ Med J 1995; 108: 167-168.
10. Ovhed I, Odeberg H, Rastam L. Opportunistic screening for hypercholesterolaemia with participants selected by the general practitioner: inclusion and drop-out rate. Fam Pract 1991; 8: 360-366.
11. Himmel W, Stolpe C, Kochen M. Information and communication about overweight in family practice. Fam Pract Res J 1994; 14: 339-351.
12. McGinnis JM, Foege WH. Actual causes of death in the United States. JAMA 1993; 270: 2207-2212.
13. Demarest S, Tafforeau J, Leurquin P et al. The health of the Belgian population. The Health Interview Survey of 1997. Brussels: COOV Scientific Institute Public Health, 1998.
14. Centers for Disease Control and Prevention. Cigarette smoking among adults: United States, 1998. MMWR 2000; 49: 881-884.
15. Fredman L, Sexton M, Cui Y et al. Cigarette smoking, alcohol consumption, and screening mammography among women ages 50 and older. Prev Med 1999; 28: 407-417.
16. Ostroff JS, Buckshee N, Mancuso CA et al. Smoking cessation following CT screening for early detection of lung cancer. Prev Med 2001; 33: 613-621.
17. Mann JI, Morgan B, Ball M et al. Hyperlipidaemia in general practice: three year follow up of an opportunistic screening project. Br J Gen Pract 1990; 40: 418-422.
18. Knowler WC, Sartor G, Melander A, Scherten B. Glucose tolerance and mortality, including a substudy of tolbutamide treatment. Diabetologia 1997; 40: 680-686.
19. Alberti KGMM. The clinical implications of impaired glucose tolerance. Diabet Med 1996; 13: 927-937.
20. Tuomilehto J, Lindstrom J, Eriksson JG et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343-1350.
21. Lawrence JM, Bennett P, Young A, Robinson AM. Screening for diabetes in general practice: cross sectional population study. BMJ 2001; 323: 548-551.
22. Welborn TA, Reid CM, Marriott G. Australian Diabetes Screening Study: impaired glucose tolerance and non-insulin-dependent diabetes mellitus. Metabolism 1997; 46: S35-S39.
23. Midthjell K, Bjorndal A, Holmen J et al. Prevalence of known and previously unknown diabetes mellitus and impaired glucose tolerance in an adult Norwegian population: indications of an increasing diabetes prevalence. Nord-Trondelag Diabetes Study. Scand J Prim Health Care 1995; 13: 229-235.
24. Raman GV, Neal A, Lewis C. A collaborative audit of the management of hypertension in general practice. Postgrad Med J 1998; 74: 165-167.
25. Barter PJ, O'Brien RC. Achievement of target plasma cholesterol levels in hypercholesterolaemic patients being treated in general practice. Atherosclerosis 2000; 149: 199-205.
26. Garmendia F, Brown AS, Reiber I, Adams PC. Attaining United States and European guideline LDL-cholesterol levels with simvastatin in patients with coronary heart disease (the GOALLS study). Corr Med Res Opin 2000; 16: 208-219.
27. Neil HA, Fowler G, Patel H et al. An assessment of the efficacy of atorvastatin in achieving LDL cholesterol target levels in patients with coronary heart disease: a general practice study. Int J Clin Pract 1999; 53: 422-426.
28. Pearson TA. The undertreatment of LDL-cholesterol: addressing the challenge. Int J Cardiol 2000; 74: S23-S28.
29. Muls E, De Backer G, De Bacquer D et al. LIPI-WATCH, a Belgian/Luxembourg survey on achievement of European Atherosclerosis Society lipid goals. Clin Drug Invest 2000; 19: 219-229.
30. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999; 281: 2005-2012.